Uncategorized
OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet Age-related Macular Degeneration
SUWON, South Korea--(BUSINESS WIRE)-- #AMD--OliX Pharmaceuticals announces the Phase 1 clinical trial of OLX10212, an investigational RNAi for the treatment of age-related macular degenerations.